Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy

BACKGROUND: People living with multiple sclerosis (MS) and other disorders treated with immunomodulatory therapies remain concerned about suboptimal responses to coronavirus disease 2019 (COVID-19) vaccines. Important questions persist regarding immunological response to third vaccines, particularly...

Descripción completa

Detalles Bibliográficos
Autores principales: Katz Sand, Ilana, Gnjatic, Sacha, Krammer, Florian, Tuballes, Kevin, Carreño, Juan Manuel, Satyanarayan, Sammita, Filomena, Susan, Staker, Erin, Tcheou, Johnstone, Miller, Aaron, Fabian, Michelle, Safi, Neha, Nichols, Jamie, Patel, Jasmin, Krieger, Stephen, Tankou, Stephanie, Horng, Sam, Klineova, Sylvia, Beck, Erin, Merad, Miriam, Lublin, Fred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794520/
https://www.ncbi.nlm.nih.gov/pubmed/36628884
http://dx.doi.org/10.1016/j.msard.2022.104486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794520/
https://www.ncbi.nlm.nih.gov/pubmed/36628884
http://dx.doi.org/10.1016/j.msard.2022.104486

Ejemplares similares